Join our daily newsletter At The Bell to receive exclusive market insights
- Dimerix (DXB) enters an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.0 clinical study
- The study, which is already approved and recruiting in India, will recruit 600 patients across India and Australia
- The CLARITY 2.0 study will test Dimerix’s drug candidate, DMX-200, in COVID-19 patients with respiratory complications
- An initial six sites will begin recruitment for the study across New South Wales, Victoria, and Queensland once regulatory and ethics approval are received
- Company shares are up 3.64 per cent to trade at 28.5 cents
Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.0 clinical study.
Already approved and open for recruitment in India, the CLARITY 2.0 study will recruit 600 patients across both India and Australia, with the NHMRC CTC to be the local sponsor in Australia.
The study will test Dimerix’s drug candidate, DMX-200, in COVID-19 patients with respiratory complications.
DMX-200 is being studied as part of two investigator-led studies in COVID-19 patients who’ve displayed respiratory complications.
An initial six sites will begin recruitment for the study across New South Wales, Victoria, and Queensland once regulatory and ethics approval are received.
Director of the NHMRC Clinical Trial Centre Professor Meg Jardine said he was delighted to be a part of a team working towards a treatment that could benefit COVID-19 patients globally.
“A safe, affordable, and effective oral treatment would be a huge advance in the fight against COVID-19. Even with the widespread uptake of vaccines, there will be some who remain susceptible to the virus. Improving treatments for patients hospitalised with COVID-19 remains crucial.”
If the study is successful, the company said DMX-200 would likely be effective against the different COVID-19 strain mutations based on its mechanism of action.
Dimerix also said its balance sheet is the strongest it’s ever been after receiving $24 million from a recent share purchase plan and two-tranche placement. The funds enabled the company to include its drug candidate in the additional CLARITY 2.0 territories, as well as advance DMX-700 through pre-clinical development and towards the clinic.
Company shares were up 3.64 per cent to trade at 28.5 cents at 11:23 am AEDT.
